EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies

Ioannis A Voutsadakis, Athina Stravodimou

Anticancer Research · 2023

DOI: 10.21873/anticanres.16241 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Anticancer Research, 2023. Verfasst von Ioannis A Voutsadakis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Algoma District Cancer Program, Sault Area Hospital, Sault Ste Marie, ON, Canada; ivoutsadakis@nosm.ca. Hauptthemen laut MEDLINE: Breast Neoplasms, Genes, BRCA2. Die Arbeit wurde bisher 31-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGenes, BRCA2FemaleHumansBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinDNA DamageHomologous RecombinationMutationPoly(ADP-ribose) Polymerase InhibitorsMolecular Targeted Therapy

Stichwörter der Autor:innen

Homologous recombinationPARPolaparibreviewtalazoparibtriple-negative

Substanzen

Biomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Algoma District Cancer Program, Sault Area Hospital, Sault Ste Marie, ON, Canada; ivoutsadakis@nosm.ca.
  • Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada.
  • Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Zitieren

APA

Voutsadakis, I. A., & Stravodimou, A. (2023). Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies. Anticancer Research. https://doi.org/10.21873/anticanres.16241

Vancouver

Voutsadakis IA, Stravodimou A. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies. Anticancer Research. 2023. doi:10.21873/anticanres.16241

BibTeX
@article{Voutsadakis2023,
  author = {Voutsadakis, Ioannis A and Stravodimou, Athina},
  title = {Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16241}
}
Kostenlos starten →